

Tofogliflozin most effective with high baseline insulin

October 24 2017



(HealthDay)—The sodium glucose co-transporter 2 inhibitor

tofogliflozin is effective for reducing fasting plasma glucose and body weight, particularly in patients with a high insulin level at baseline, according to a study published online Oct. 15 in the *Journal of Diabetes Investigation*.

Kazuyuki Tobe, M.D., Ph.D., from the University of Toyama in Japan, and colleagues conducted a sub-analysis of a multicenter, open-label, 52-week, randomized controlled trial of tofogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus. Patients were categorized into tertiles by baseline [insulin](#) level: low (L) insulin ($\leq 5.6 \mu\text{U}/\text{mL}$), medium (M) insulin (5.6 to $10 \mu\text{U}/\text{mL}$), and high (H) insulin ($> 10 \mu\text{U}/\text{mL}$).

The researchers found that HbA1c, fasting [plasma glucose](#) levels, and [body weight](#) were significantly reduced from the baseline in all three groups. The changes in levels of plasma glucose $\text{AUC}_{0-2 \text{ hours}}$, C-peptide index $\text{AUC}_{0-2 \text{ hours}}$ during the meal tolerance tests, and the insulin secretion index were the largest in the H group. The three groups were similar in terms of incidence of drug-related adverse events.

"Although tofogliflozin was effective regardless of baseline insulin level, it showed the highest efficacy in the H group," conclude the authors.

The authors disclosed financial ties to the pharmaceutical industry. Chugai Pharmaceutical Co. funded the original phase 3 trial.

More information: [Abstract/Full Text](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Tofogliflozin most effective with high baseline insulin (2017, October 24) retrieved 29 April 2024 from

<https://medicalxpress.com/news/2017-10-tofogliflozin-effective-high-baseline-insulin.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.